

DAFTAR PUSTAKA

- Abduljalil, K., Furness, P., Johnson, T.N., Rostami-Hodjegan, A., Soltani, H., Furness, P. 2012. *Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiological based pharmacokinetic modelling*. ClinPharmacokinet, 51:365-96.
- Aiuti, F. & Mezzaroma, I. 2006. *Failure to Reconstitute CD4+ T-Cells Despite Suppression of HIV Replication under HAART*. AIDS Review. 888-97.
- Antiretroviral Pregnancy Registry Steering Committee. 2013. *Antiretroviral Pregnancy Registry Interim Report for 1 January 1989 through 31 July 2013*. Wilmington, NC: Registry Coordinating Center. Available at: www.APRegistry.com.
- Arrivé, E., Newell, M., Ekouevi, D., Chaix, M., Thiébaud, R., Masquelier, B., Leroy, V., DePerre, P., Rouzioux, C., Dabis, F. 2007. *Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: A meta-analysis*. International Journal of Epidemiology, 36(5), pp.1009–1021. doi:10.1093/ije/dym104
- Astoro, N.W., Djauzi, S., Djoerban, Z., Prodjosudjadi, W. 2007. *Quality of life of HIV Patients and Influential Factors*. Acta Med Indones-Indones J Intern Med, 39(1), p1-7
- Baker, J., Peng, G., Rapkin, J., Krason, D., Reilly, C., Cavert, W.P., Abrams, D.I., MacArthur, R.D., Keith, H., Neaton, J.D. for the Terry Bein Community Programs for Clinical Research on AIDS (CPCRA). 2008. *Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases*. Journal Acquired Immune Deficiency Syndrome, 48(5), pp. 541–546. doi:10.1097/QAI.0b013e31817bebb3.Poor.
- Binquet, C., Chene, G., Jackmin-Gadda, Journot, V., Saves, M., Lacoste, D., Dabis, F. 2001. *Modelling Changes In CD4-positive T-Lymphocyte Counts*

- after the start of Highly Active Antiretroviral Therapy and the Relation with Risk of Opportunistic Infections*. American Journal of Epidemiology. 153(4), p386-393.
- Briand, N., Warszawski, J., Mandelbrot, L. 2013. *ANRS-APFCO1-CO11 Study Group. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviraltherapy era?*. Clin Infect Dis,57(6):903-14.
- Calles, N.R., Evans, D., Terlonge, D. 2010. *Pathophysiology of the human immunodeficiency virus*. Baylor Pediatrics International AIDS Initiative, pp. 7–14. Available at: <http://www.bipai.org/Curriculum/HIV-Curriculum/Pathophysiology-of-HIV.aspx>.
- Ceccaldi, P.F., Ferreira, C., Gavard, L. 2008. *Placentaltransfer of enfuvirtide in the ex vivo human placenta perfusion model*. Am J Obstet Gynecol,198(4):433.e1-2
- Chiappini, E., Galli, L., Giaquinto, C. 2013. *European Pregnancy and Pediatric HIV Cohort Colloboration study group in EuroCoord. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants*. AIDS. 27(6):991-1000 doi:10.1097/QAD.0b013e32835cffb1
- Copp, A.J., Stanier, P., Greene, N.D.E. 2013. *Neural tube defects: recent advances, unsolved questions and controversies*. Lancet Neurol, 12:799-801
- Denoeud-Ndam, L., Fourcade, C., Ogouyemi-Hounto, A. 2013. *Predictive Factors of Plasma HIV Supression during Pregnancy: A Prospective Cohort Study in Benin*. Plos One. 8(3):e59446
- Departemen Farmakologi-Terapeutik, FK UI. 2009. Buku ajar Farmakologi dan Terapeutik.
- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. 2017. *Laporan Perkembangan HIV/AIDS 7 Penyakit Menular Seksual (PIMS) Triwulan I Tahun 2017*. pp. 1–402.
- Fanales-Belasio, E., Raimondo, M., Suligo, B., Buttò, S. 2010. *HIV virology and*

pathogenetic mechanisms of infection: a brief overview. Ann Ist Super Sanità, 46(1), pp. 5–14. doi: 10.4415/ANN.

Farahani, M., Novitsky, V., Wang, R., Bussmann, H., Moyo, S., Musonda, R.M., Moeti, T., Makhema, J.M., Essex, M., Marlink, R. 2016. *Prognostic Value of HIV-1 RNA on CD4 Trajectories and Disease Progression Among Antiretroviral-Naive HIV-Infected Adults in Botswana: A Joint Modeling Analysis*. AIDS RESEARCH AND HUMAN RETROVIRUSES, 32(6), pp. 573–578. doi: 10.1089/aid.2015.0348.

Ford, N., Calmy, A., Andrieux-Meyer, I. 2013. *Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis*. AIDS. 27:1135-43

Ford, N. F., Mofensonb, L., Shubberc, Z., Calmyd, A., Andrieux-Meyere, I., Vitoriaa, M., Shaffera, N., Renauda, F. 2014. *Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis*. AIDS. 28, pp. 123–131. doi: 10.1097/QAD.0000000000000231

Fournier, S., Chaffaut, C., Maillard, A., Loze, B., Lascoux, C., Ge´rard, L., Timsit, J., David, F., Bergmann, J.F., Oksenhendler, E., Sereni, D., Chevret, S., Molina, J.M. 2005. *Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study*. British HIV Association, pp. 129–134

Gilleece, Y., Tariq, S., Bamford, A., Bhagani, S., Byrne, L., Clarke, E., Clayden, P., Croston, M., Lyall, H., Pallfreeman, A., Metcalfe, R., Sonecha, S., Rubinstein, L., Tookey, P., Thorley, L., Utting, D., Tosswill, J., Wright, A., Welch, S. 2018. *British HIV Association guidelines for the management of HIV infection in pregnant women*. NHS.

HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Panel Members and Consultants. 2015. *Management of the Treatment Poor Response CD4 AIDS*.

HIV Surrogate Marker Collaborative Group. 2000. *Human Immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis*. AIDS Research and Human

Retroviruses. 16(12), 1123-1133

Holmes, K., Sparling, P., Stamm, W., Piot, P., Wasserheit, J., Corey, L., Cohen, M. 2008. *Sexually Transmitted Diseases*. 4th Ed. McGraw-Hill New York.

Huang, P., Tan, J., Ma, W., Zheng, H., Lu, Y., Wang, N., Peng, Z., Yu, R. 2015. *Outcomes of antiretroviral treatment in HIV-infected adults : a dynamic and observational cohort study in Shenzhen, China 2003-2014*. BMJ Open, pp. 9–16. doi: 10.1136/bmjopen-2014-007508.

Kasper, D. 2012. *Human Immunodeficiency Virus Disease: AIDS and Related Disorders*. Harrison's Principles of Internal Medicine. 9th Ed.

Kelley, C.F., Kitchen, C.M.R., Hunt, P.W., Rodriguez, B., Hect, F.M., Kitahata, M., Crane, H.M., Willig, J., Mugavero, M., Saag, M., Martin, J.M., Deeks, S.G. 2009. *Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment*. Clinical and Infectious Diseases. 48(6),787-794

Kementrian Kesehatan Republik Indonesia (2014a). 2014. Pedoman Nasional Pencegahan Penularan HIV dari ibu ke anak (PPIA). Edisi kedua

Kementrian Kesehatan Republik Indonesia (2014b). 2014. Pedoman Pengobatan Antiretroviral.

Kirmse, B., Baumgart, S., Rakhmanina, N. 2013. *Metabolic and mitochondrial effects of antiretroviral drug exposure in pregnancy and post partum: implication for fetal and future health*. Semin Fetal Neonatal Med. 18(1): 48-55

Kunstel, K. 2008. *AIDS/HIV in pregnancy*. Handbook of Nutrition and Pregnancy. Humana Press, p161-174. doi: 10.1007/978-1-59745-112-3

Maartens, G.M., Celum, C., Lewin, S.R. 2014. *HIV infection: Epidemiology, pathogenesis, treatment, and prevention*. The Lancet. Elsevier Ltd, 384(9939), pp. 258–271. doi: 10.1016/S0140-6736(14)60164-1.

May, M., Gompels, M., Delpech, V., Porter, K., Post, F., Johnson, M., Dunn, D., Palfreman, A., Gilson, R., Gazzard, B., Hill, T., Walsh, J., Fisher, M., Orkin, C., Ainsworth, J., Bansi, L., Phillip, A., Leen, C., Nelson, M., Anderson, J., Sabin, C. 2012. *Impact of late diagnosis and treatment on*

- life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.* BMJ,343d6016
- McKeown, D.A., Rosenvinge, M., Donaghy. 2010. *High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.* AIDS. 24(15):2416-8
- Mildvan, D., Bosch, R.J., Kim, R.S., Spritzler, J., Haas, D.W., Kuritzkes, D., Kagan, J., Nokta, M., DeGruttola, V., Moreno, M., Landay, A. 2018. *Immunophenotypic Markers and Antiretroviral Therapy (IMART): T Cell Activation and Maturation Help Predict Treatment Response.* 10003, pp. 1811–1820
- Mylonakis, E., Paliou, M., Rich, J.D. 2001. *Plasma Viral load testing in the management of HIV Infection.* Am Fam Physician, 63, p. 483–90, 495–6.
- Nasronudin. 2012. *HIV & AIDS Pendekatan Biologi Molekuler Klinis & Sosial.* 2nd Ed. Airlangga University Press.
- Nightingale, S.L. 1998. *From the Food and Drug Administration.* JAMA. 280:1472
- Nobrega, I., Travassos, A.G., Haguilar, T., Amorim, F., Brites, C. 2013. *Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women.* AIDS Res Hum Retroviruses. 29(11), pp. 10–13. doi: 10.1089/aid.2013.0059.
- Ondoa, P., Koblavi-Dème, S., Borget, M.Y., Nolan, M.L., Nkengasong, J.N., Kestens, L. 2005. *Assessment of CD 8+ T cell immune activation markers to monitor response to antiretroviral therapy among HIV- 1 infected patients in Côte d’Ivoire.* Clinical and Experimental Immunology. 140(1), 138-148. doi:10.1111/j.1365-2249.2005.02734.x
- Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. 2013. *Recommendation for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States.* Available at

<http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf>.

Accessed 13 Januari 2013.

PKBI DIY. Data Kasus HIV dan AIDS D.I. Yogyakarta Update Triwulan 1 Tahun 2015. Available at: <http://pkbi-diy.info/?p=3964>.

Ransom, C.E., Huo, Y., Patel, K. Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. 2013. *Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy*. J Acquir Immune Defic Syndr. 64(4):374-81

Read, P.J., Mandallia, S., Khan, P. 2012. *When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?* AIDS. 26(9):1095-103

Shapiro, R.L., Hughes, Ogwu, A. 2010. *Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana*. The New England Journal of Medicine. 362;24

Sibiude, J., Warszawski, J., Tubiana, R. 2012. *Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?* Clin Infect Dis. 54:1348-60

Stuart, J.C., Hamann, D., Borleffs, J., Roos, M., Miedema, F., Boucher, C., deBoer, R. 2002. *Reconstitution of naive T cells during antiretroviral treatment of HIV-infected adults is dependent on age*. AIDS. 16:2263-2266

Szyld, E., Warley, E.M., Freimanis, L. 2006. *Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth*. AIDS. 20:2345-53

Tan, R., Westfall, A.O., Willig, J.H., Mugavero, M.J., Saag, M.S., Kaslow, R.A., Kempf, M.C. 2008. *Clinical Outcome of HIV-Infected Antiretroviral-Naive Patients With Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy*. 47(5), pp. 553–558.

Thorne, C. 2000. *Combination antiretroviral therapy and duration of pregnancy. The European Collaborative Study and the Swiss Mother & Child HIV Cohort Study*. AIDS. 14(18), pp. 2913–2920.

Townsend, C.L., Cortina-Borja, M., Peckham, C.S. 2008. *Low rates of mother-to-*

child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2:973-981

Tuboi, S.H., Brinkhof, M.W.G., Egger, M., Stone, R.A., Braitstein, P., Wash, D., Sprinz, E., Dabis, F., Hanson, L.H., Schecher, M. 2007. *Discordant responses to potent antiretroviral treatment in previously naïve HIV-1 infected adults initiating treatment in resource-strained countries.* Journal of Acquired Immune Deficiency Syndrome. 45(1), 52-59

UNAIDS. 2016. *Global AIDS Update 2016.* World Health Organization. p. 422. doi: ISBN 978-92-9253-062-5.

Vinot, C., Gavard, L., Treluyer, J.M. 2013. *Placental transfer of maraviroc in an ex vivo human cotyledon perfusions model and influence of ABC transporter expression.* Antimicrob Agents Chemother. 57(3): 1415-20. doi:10.1128/AAC.1821-12

Warszawski, J., Tubiana, R., Le Chenadec, J. 2008. *Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.* AIDS. 22(2):289-99

Waters, Laura., Williams, I. 2016. *BHIVA guidelines for the treatment of British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update).* NHS.

Watts, D.H. and Mofenson, L.M. 2012. *Antiretrovirals in Pregnancy: A Note of Caution.* The Journal of Infectious Diseases. 206, pp. 1639–1641. doi: 10.1093/infdis/jis581.

World Health Organization. 2016a. *Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach.* World Health Organization, p. 155 p. doi: 10.1016/j.jped.2014.04.007

World Health Organization, S.E.A.R. 2016b. *HIV / AIDS in the South-East Asia Region Progress Report 2016.* WHO Library Cataloguing-in-Publication data.



UNIVERSITAS
GADJAH MADA

**HUBUNGAN ANTARA LAMA PEMAKAIAN ANTIRETROVIRAL THERAPY (ART) DENGAN VIRAL LOAD
PADA IBU HAMIL
PENDERITA HIV**

SINTYCHE E. MARPAUNG, Dr. dr. Diah Rumekti Hadiati, MSc, SpOG(K); dr. Shinta Prawitasari, MKes, SpOG(K)
Universitas Gadjah Mada, 2018 | Diunduh dari <http://etd.repository.ugm.ac.id/>